When was DermTech founded?

DermTech was founded in 1996 and raised its 1st funding round 16 years after it was founded.

Where is DermTech located?

DermTech is headquartered in San Diego, United States. It is registered at La Jolla, California.

How many employees does DermTech have?

As of Sep 30, 2026, the latest employee count at DermTech is 69.

Is DermTech a funded company?

DermTech is a funded company, having raised a total of $24.4M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 10, 2012.

When was the latest funding round of DermTech?

DermTech's latest funding was a $***** Post IPO round on Mar 13, 2020, with participation from 0 investor.

What is the annual revenue of DermTech?

Annual revenue of DermTech is between $10M and $50M as on Dec 31, 2023

Where does DermTech rank among its competitors?

DermTech ranks 4th amongst 128 active competitors, of which 29 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was ChromaCode, which secured $3.85M in Jan, 2025.

Who are the top competitors of DermTech?

DermTech's top competitors include Molbio Diagnostics, Castle Biosciences and ChromaCode. Among them, ChromaCode secured the most recent funding round in January, 2025.

DermTech - 2026 Company Profile, Funding & Competitors

DermTech is an acquired company based in San Diego (United States), founded in 1996. It operates as a Provider of adhesive patch biopsy for skin cancer diagnostics. DermTech has raised $24.4M in funding. The company has 128 active competitors, including 29 funded and 28 that have exited. Its top competitors include companies like Molbio Diagnostics, Castle Biosciences and ChromaCode.

Company Details

DermTech develops qPCR assays and diagnostic aides for skin samples collected non-invasively to detect melanoma and skin cancer. It has a proprietary technology that allows skin 'biopsies' to be taken by applying an adhesive patch on the patient's skin. This patch can able to take cells present in the outermost skin layer and then analyze them for gene expression levels.

Website: dermtech.com
Social
Registered Address: La Jolla, California

Key Metrics

Founded Year

1996

Location

San Diego, United States

Stage

Acquired

Total Funding

$24.4M in 6 rounds

Latest Funding Round

Post IPO, Mar 13, 2020, $*****

Investors

Jacob Hanoch & 4 more

Ranked

4^th among 128 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2023

Employee Count

69 as on Sep 30, 2026

Similar Companies

Molbio Diagnostics & 65 more

Exit Details

Acquired by Constellation Alpha (Mar 18, 2019)

View DermTech's full profile

DermTech is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Dermtech, Inc. CIN: 1651944 , United States, Active		$10M - $50M (As on Dec 31, 2023)	-	-
Dermtech International CIN: 330708997 , United States, Active	Dec 31, 1999	-	4 (As on Dec 31, 2024)	-

DermTech got acquired by Constellation Alpha on Mar 18, 2019.

Click here to take a look at DermTech's acquisition in detail

DermTech has raised a total funding of $24.4M over 6 rounds. Its first funding round was on Apr 10, 2012. DermTech has 4 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of DermTech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 13, 2020	5998548	Post IPO	1663122	6584177	3049084	9436418
Feb 01, 2018	8539050	Post IPO	5342769	8154031	4083744	RTW Investments
Nov 12, 2015	6193936	Series B	8638497	9137179	8377843	9580506

Access funding benchmarks and valuations. Sign up today!

View details of DermTech's funding rounds and investors

DermTech's employee count trend

DermTech has 69 employees as of Sep 26. Here is DermTech's employee count trend over the years:

Uncover DermTech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DermTech include Molbio Diagnostics, Castle Biosciences and ChromaCode. Here is the list of Top 10 competitors of DermTech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Molbio Diagnostics 2000, Salcete (India), Public	Developer of point-of-care molecular diagnostic platform for infectious disease detection	$124M	Motilal Oswal, Temasek & 36 others	74/100
2nd	Castle Biosciences 2008, Friendswood (United States), Public	Provider of diagnostic devices for treating cancer	$62M	Industry Ventures, Health Quest Capital & 10 others	66/100
3rd	ChromaCode 2012, Carlsbad (United States), Series C	Digital molecular biology analytics for disease management	$95M	Northpond Ventures, New Enterprise Associates ... & 9 others	55/100
4th	DermTech 1996, San Diego (United States), Acquired	Provider of adhesive patch biopsy for skin cancer diagnostics	$24.4M	RTW Investments, Van Herk Groep & 3 others	56/100
5th	Biofire Diagnostics 1990, Salt Lake City (United States), Acquired	Provider of molecular diagnostic solutions for the detection of genetic conditions	$84M	Founders Fund, Athyrium Capital Management ... & 8 others	54/100
6th	Diagnoplex 2005, Lausanne (Switzerland), Acquired	Molecular diagnostics for colorectal cancer.	$9.68M	NeoMed, Novartis Venture Fund & 2 others	53/100
7th	NeuMoDx 2012, Ann Arbor (United States), Acquired	Developer of a platform for low cost molecular testing	$66M	Arboretum Ventures, Wolverine Venture Fund ... & 3 others	52/100
8th	QuantuMDx Group 2008, Newcastle Upon Tyne (United Kingdom), Series D	Manufacturer of molecular diagnostic platforms and assays for infectious diseases	$57.3M	Adjuvo, WG Partners & 3 others	49/100
9th	Quantalife 2008, Pleasanton (United States), Acquired	Life science research and clinical diagnostics solutions provider, powering possibilities	$28.7M	Paladin Capital, Vital Venture Capital & 3 others	48/100
10th	Co-Dx 2013, Salt Lake City (United States), Public	Provider of genomics-based information and solutions for transplant patients	$1.1M	NIH, SALSS	48/100